Reduction of hepatic fibrosis by overexpression of von Hippel-Lindau protein in experimental models of chronic liver disease.
Ontology highlight
ABSTRACT: Hypoxia-inducible factor (HIF)-1? and HIF-2? play an important role in liver fibrosis. von Hippel-Lindau protein (VHL), a key mediator of HIF-?, regulates fibrosis in an organ- and cell-specific way. In this study, human liver samples were collected from hepatitis C-, alcoholic-, and cholestatic-associated fibrotic and healthy individuals. Two mouse models of liver fibrosis were established: bile duct ligation and carbon tetrachloride injection. We constructed adenovirus vectors to overexpress VHL, normoxia-active HIF-?, and lentiviral vectors to silence HIF-?. The results showed that liver sections from fibrosis patients had a lower level of VHL and higher levels of HIF-1? and HIF-2? compared with healthy sections, a finding which was confirmed in mice. Overexpression of VHL attenuated liver fibrosis, downregulated fibrogenic genes, and inhibited liver inflammation, apoptosis, and angiogenesis. Overexpression of VHL was more successful at inhibiting fibrosis compared with silencing HIF-1? plus HIF-2?. Normoxia-active HIF-1? or HIF-2? prevented the inhibitory effect of VHL on liver fibrosis, indicating that attenuating fibrosis via VHL is HIF-1?- and HIF-2?-dependent to some extent. In addition, overexpression of VHL inhibited mouse hepatic stellate cells activation and proliferation and promoted apoptosis. Taken together, VHL may be considered a new target to inhibit liver fibrosis.
SUBMITTER: Wang J
PROVIDER: S-EPMC5253623 | biostudies-literature | 2017 Jan
REPOSITORIES: biostudies-literature
ACCESS DATA